From the results of measuring the expression levels of Bcl2, Bax, PCNA, LDH-A, pan-AKT, phospho-AKT (Ser 473) and the ratio of phospho-AKT/AKT in the lysates of the tumors induced by SK-OV-3 clones, we conclude that overexpression of METCAM/MUC18 may decrease in vivo tumorigenesis and malignant propensity of ovarian carcinoma cells by reducing the absolute levels of pan-AKT and phospho-AKT, which in turn decreases proliferation, aerobic glycolysis and angiogenesis but not by altering apoptosis/anti-apoptosis and survival pathways [23]. This evidence concerns the gene MCAM and ovarian carcinoma.